Contraception
Volume 73, Issue 3 , Pages 223-228 , March 2006

Risk of nonfatal venous thromboembolism in women using a contraceptive transdermal patch and oral contraceptives containing norgestimate and 35 μg of ethinyl estradiol

Received 18 November 2005 ,Revised 9 January 2006 ,Accepted 10 January 2006.

References 

  1. http://www.fda.gov/cder/drug/infopage/orthoevra/default.htm.
  2. van den Heuvedl MW, van Bragt AJM, Alnabawy A, Kaptein M. Comparison of ethinylestradiol pharmacokinetics in three hormonal contraceptive formulations: the vaginal ring, the transdermal patch and an oral contraceptive. Contraception. 2005;72:168–174
  3. World Health Organization . Venous thromboembolic disease and combined oral contraceptives: results of international multicentre case-control study. WHO Collaborative Study of Cardiovascular Disease and Steroid Hormone Contraception. Lancet. 1995;346:1575–1582
  4. Gomes MP, Deitcher SR. Risk of venous thromboembolic disease associated with hormonal contraceptives and hormone replacement therapy: a clinical review. Arch Intern Med. 2004;164:1965–1976
  5. Jick H, Jick SS, Gurewich V, Myers MW, Vasilakis C. Risk of idiopathic cardiovascular death and nonfatal venous thromboembolism in women using oral contraceptives with differing progestagen components. Lancet. 1995;346:1589–1593
  6. Jick H, Kaye JA, Vasilakis-Scaramozza C, Jick SS. Risk of venous thromboembolism among users of third generation oral contraceptives compared with users of oral contraceptives with levonorgestrel before and after 1995: cohort and case-control analysis. BMJ. 2000;321:1190–1195
  7. Vandenbroucke JP, Rosing J, Bloemenkamp KW, et al. Oral contraceptives and the risk of venous thrombosis. N Engl J Med. 2001;344:1527–1535
  8. World Health Organization . Effect of different progestagens in low oestrogen oral contraceptives on venous thromboembolic disease. WHO Collaborative Study of Cardiovascular Disease and Steroid Hormone Contraception. Lancet. 1995;346:1582–1588
  9. Sibai BM, Odlind V, Meador ML, Shangold GA, Fisher AC, Creasy GW. A comparative and pooled analysis of the safety and tolerability of the contraceptive patch (Ortho Evra/Evra). Fertil Steril. 2002;77(Suppl 2):S19–S26
  10. Black C, Kaye JA, Jick H. Clinical risk factors for venous thromboembolus in users of the combined oral contraceptive pill. Br J Clin Pharmacol. 2002;53:637–640
  11. Kleinbaum DG, Kupper LL, Muller KE, Nizam A. Applied regression analysis and other multivariable methods. 3rd ed.. Pacific Grove (CA): Duxbury Press; 1998;[Chapter 24, pp 687-709, and Chapter 22, section 22-3-2]
  12. Oger E, Alhenc-Gelas M, Lacut K, et al. Differential effects of oral and transdermal estrogen/progesterone regimens on sensitivity to activated protein C among postmenopausal women: a randomized trial. Arterioscler Thromb Vasc Biol. 2003;23:1671–1676
  13. Scarabin PY, Oger E, Plu-Bureau G. Differential association of oral and transdermal oestrogen-replacement therapy with venous thromboembolism risk. Lancet. 2003;362:428–432
  14. Vasilakis-Scaramozza C, Jick H. Risk of venous thromboembolism with cyproterone or levonorgestrel contraceptives. Lancet. 2001;358:1427–1429
  15. Vandenbroucke JP, Koster T, Briet E, Reitsma PH, Bertina RM, Rosendaal FR. Increased risk of venous thrombosis in oral-contraceptive users who are carriers of factor V Leiden mutation. Lancet. 1994;344:1453–1457
  16. Jick H, Garcia L, Rodrigues A, Peres Gutthann S. Principles of epidemiologic research on adverse and beneficial drug effects. Lancet. 1998;352:1767–1770
  17. Farley TM, Meirik O, Chang CL, Poulter NR. Combined oral contraceptives, smoking, and cardiovascular risk. J Epidemiol Community Health. 1998;52:775–785
  18. Lawson DH, Davidson JF, Jick H. Oral contraceptive use and venous thromboembolism: absence of an effect of smoking. Br Med J. 1977;2:729–730

PII: S0010-7824(06)00008-4

doi: 10.1016/j.contraception.2006.01.001

Contraception
Volume 73, Issue 3 , Pages 223-228 , March 2006

Article Tools